



Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

February 27, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2024-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. ET.

An audio webcast of the panel discussion will be available under the "Investors and News" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres' lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of *C. difficile* infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. For more information, please visit www.serestherapeutics.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240227103007/en/): <https://www.businesswire.com/news/home/20240227103007/en/>

Investor and Media Contacts:

Rob Windsor

Rwindsor@serestherapeutics.com

Source: Seres Therapeutics, Inc.